| |
|
| |
| CAPAS: Too Much or Not Enough? |
PharmaManufacturing.com
By Nikki Willett,
Vice president of Marketing & Regulatory Products
Pilgrim Software
A strategic CAPA plan requires transparent information and a clear understanding of root causes. Corrective and Preventive Action (CAPA) is a critical part of pharmaceutical quality systems. Failure to comply with requirements can be costly for any pharmaceutical or biopharma company, resulting in damaged reputation and profitability. But adhering to CAPA is not only a regulatory requirement — it’s sound business practice. This article examines issues and presents best practices. Click here to read entire article.
E-mail
this page
Print This Page |
|  |
 |
| |
